期刊文献+

沙利度胺联合三氧化二砷治疗骨髓增生异常综合征转化的急性红白血病一例

原文传递
导出
摘要 目的研究沙利度胺联合三氧化二砷治疗骨髓增生异常综合征(MDS)转化急性红白血病的疗效。方法对1例患者应用沙利度胺100mg/d临睡前口服;三氧化二砷10mg/d持续5~6h静脉输注,每周连用5d,共用2周,再停药2周为1个疗程。结果患者病情稳定,获部分缓解。结论沙利度胺联合三氧化二砷治疗MDS转化急性红白血病的疗效较好,可临床扩大应用。
出处 《白血病.淋巴瘤》 CAS 2009年第8期487-488,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献7

  • 1Olopada OI, Thangavelu M, Larson RA, et al. Clinic morphologic and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood, 1992, 80: 2874-2882.
  • 2Bouscary D, Ves JD, Guesnu M, et al. Fas/Apo-1 (CD95)expression and apoptosis in patients with myelodsplastic syndromes.Leukemia, 1997, 11: 839-845.
  • 3Mufti GJ. Ineffective haemapoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol, 1998, 101: 220-230.
  • 4Rara A, Lisak L, Billmeier J, et al. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leuke Lympoma, 2006, 47: 433-440.
  • 5Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol, 2007, 39: 1489-1499.
  • 6Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastie syndromes. Blood, 2001, 97: 1427-1434.
  • 7Schiller GJ, Slack J, Hainsworth B JD, et al. Phase II muhicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol, 2006, 24: 2414-2416.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部